Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 25 mar 2024 · Mean weight loss was 5.9% at three months and 11% at six months. The proportion of patients achieving > 5% weight loss was 54% at three months and 55% at six months. Weight loss was significantly lower among patients with type 2 diabetes, consistent with findings from clinical trials.

  2. Multivariable linear models were used to compare percent weight loss across categories at 6, 12, and 24 months, and Cox proportional hazards models were used to compare risk of composite CVD or death, up to 3 years after starting phentermine.

  3. 3 sty 2024 · Recent published estimates of short-term (e.g., 8 to 12 weeks) weight loss with phentermine treatment are highly variable, ranging from 3.6 to 12.1% of initial body weight [25,26,27,28,29,30,31,32]. Research on weight loss with longer-term use of phentermine is sparse.

  4. Instead, clinicians mainly prescribe phentermine to patients with obesity for the purpose of weight reduction. Moreover, because obesity is a chronic disease, many clinicians use phentermine beyond its approved “short-term” use (i.e., 12 weeks), as otherwise directed by the prescribing information.

  5. 2 gru 2021 · Long‐term weight loss maintenance was achieved by 65.3% of patients. Almost all (96.2%) were on ≥1 AOM at 2 years, with metformin, phentermine, and topiramate among the most prescribed. AOM usage and older age demonstrated trends toward predicting weight loss maintenance over 2 years.

  6. Weight loss of 5% to 10% of initial weight, achieved through intensive lifestyle intervention, reduces cardiovascular disease (CVD) risk factors, prevents or delays the development of type 2 diabetes, and improves other health consequences of obesity. 2,3 Although improvements in some CVD risk factors can be seen with sustained weight loss as ...

  7. Recent findings: Recent research on phentermine is sparse and consists primarily of observational studies with methodologic limitations. These studies suggest that phentermine use is associated with clinically significant weight loss in adults and that the medication is generally well tolerated.